

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**信銘生命科技集團有限公司**  
**Aceso Life Science Group Limited**  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 00474)**

**PROFIT WARNING**

This announcement is made by Aceso Life Science Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company and potential investors that, based on the preliminary assessment of the Group’s unaudited consolidated management accounts for the six months ended 30 September 2023 (“**Reporting Period**”) and information currently available to the Board, the Group is expected to record a loss for the Reporting Period of approximately HK\$250 million, as compared to the loss of approximately HK\$4 million for the corresponding period in 2022. The increase in the Group’s loss is mainly attributable to (i) the increase in fair value losses on financial assets at FVTPL and (ii) increase in fair value losses on investment properties.

The information contained in this announcement is only based on a preliminary assessment by the Board with reference to the unaudited consolidated management accounts for the Reporting Period of the Group and on the information available for the time being, but not on any data or information reviewed by the independent auditor or audit committee of the Company. The information may be subject to adjustments as the Company is still in the process of preparing and finalising the Group’s unaudited consolidated interim results for the Reporting Period. Details of the Group’s interim financial results and performance for the Reporting Period will be disclosed in the interim results announcement of the Company which is expected to be announced in late November 2023.

Shareholders of the Company and potential investors are reminded to exercise caution when dealing in the shares or other securities of the Company.

By order of the Board  
**Aceso Life Science Group Limited**  
**Fok Chi Tak**  
*Executive Director*

Hong Kong, 20 November 2023

*As at the date of this announcement, the Board comprises three executive directors, namely Mr. Xu Haiying, Mr. Fok Chi Tak and Dr. Zhiliang Ou, JP (Australia); and three independent non-executive directors, namely Mr. Mak Yiu Tong, Mr. Lam Kwan Sing and Mr. Chan Ming Sun Jonathan.*